Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

0.7500 -0.0384 (-4.87%)
Streaming Delayed Price Updated: 3:55 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 215,724
Open 0.8000
Bid (Size) 0.7700 (1)
Ask (Size) 0.8000 (20)
Prev. Close 0.7884
Today's Range 0.7400 - 0.8262
52wk Range 0.6208 - 3.870
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that... 
From Altamira Therapeutics
Via AccessWire
Exposures Product Safety
Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study
 
Via Benzinga

Performance

YTD
-60.94%
-60.94%
1 Month
-14.29%
-14.29%
3 Month
-23.09%
-23.09%
6 Month
-56.14%
-56.14%
1 Year
-74.56%
-74.56%

More News

Read More
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Earnings Scheduled For March 10, 2022
Via Benzinga
Altamira Therapeutics Issues Shareholder Letter
From Altamira Therapeutics
Via AccessWire
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
From Altamira Therapeutics
Via AccessWire
Why Altamira Therapeutics Stock Is Soaring
Via Benzinga
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics FY 2021 Earnings Conference Call On April 12, 2022 At 08:00 AM ET
Via Benzinga
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
From Altamira Therapeutics
Via AccessWire
Topics Earnings
Exposures Financial
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
From Altamira Therapeutics
Via AccessWire
95 Biggest Movers From Friday
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Orphazyme Shares Plunge
Via Benzinga
Why Are Altamira Therapeutics Shares Gaining Today?
Via Benzinga
Mid-Day Market Update: Gold Down 1%; Clearside Biomedical Shares Jump
Via Benzinga
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
From Altamira Therapeutics
Via AccessWire
50 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
30 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
88 Biggest Movers From Yesterday
Via Benzinga
Altamira, Nuance Pharma Ink Licensing Pact For Bentrio In China, Additional Asian Markets
Via Benzinga
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
From Altamira Therapeutics
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.